Salix bumps up GI portfolio with Oceana buy for $300m
This article was originally published in Scrip
Executive Summary
Salix Pharmaceuticals is to buy privately held Oceana Therapeutics for $300 million in cash to gain access to Oceana's urology treatments Deflux and Solesta.